China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SHE:300294)

Market Cap	8.81B -41.1%
Revenue (ttm)	1.84B +1.2%
Net Income	3.44M -99.1%
EPS	0.01 -99.1%
Shares Out	504.25M
PE Ratio	2,564.48
Forward PE	26.27
Dividend	0.22 (1.25%)
Ex-Dividend Date	n/a

Volume	5,827,792
Average Volume	4,542,085
Open	17.39
Previous Close	17.85
Day's Range	17.39 - 17.88
52-Week Range	17.28 - 27.99
Beta	0.22
RSI	36.53
Earnings Date	Apr 25, 2026

About SHE:300294

China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the research, development, production, and sale of blood products in China. It offers blood products, such as human serum albumin; human, intravenous, freeze-dried intravenous, hepatitis B, tetanus, and rabies immunoglobulin; and human fibrinogen, prothrombin complex, and coagulation factor VIII. The company also provides compound bone peptide, oxytocin, heparin sodium injection, posterior pituitary, and carboprost tromethamine injection. In addition, it engages in research, devel...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 1,947
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300294

Financial Performance

In 2025, SHE:300294's revenue was 2.06 billion, an increase of 18.69% compared to the previous year's 1.73 billion. Earnings were 112.70 million, a decrease of -71.61%.